News | July 20, 2012

ASTRO Criticizes Proposed Drops in Reimbursement for IMRT, SBRT

July 20, 2012 — On July 6, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule that would revise several reimbursement payment policies and rates for services furnished under the Medicare Physician Fee Schedule (MPFS) as of January 1, 2013. The proposed changes reflect an overall 15 percent reduction in payment for radiation oncology services, equaling a $300 million loss for the provision of cancer care services, according to the American Society for Radiation Oncology (ASTRO). The most significant portion of the cut, 7 percent, is due to a change by CMS in the treatment times for IMRT (intensity-modulated radiation therapy) and SBRT (stereotactic body radiation therapy) procedure codes.  

“These cuts would have a negative impact on patient access to life-saving cancer treatment, particularly in rural communities, and could jeopardize patient safety,” said Leonard L. Gunderson, M.D., M.S., FASTRO, chairman of ASTRO’s board of directors. “ASTRO believes that CMS should utilize the rigorous processes and methodologies already in place and utilized for the past 20 years to set reimbursement rates. ASTRO supports the American Medical Association’s (AMA) RUC process as the most appropriate process to value practice expenses, and ASTRO welcomes the opportunity for a comprehensive review of treatment costs. The proposed cuts to radiation oncology reimbursement are more than double what has been proposed for any other healthcare providers. It is essential to protect and to strengthen access to safe cancer care nationwide. 

“Radiation oncology is an important tool in the fight against cancer. Radiation therapy is a safe treatment option with a long track record of effectively treating cancer with minimal side effects. In the last 25 years, the survival rate for many cancer patients has increased steadily. For example, in the mid-1970s, the five-year survival rate for breast cancer was 75 percent; for prostate cancer it was 69 percent. Today, the five-year survival rate is 90 percent for breast cancer and 99 percent for prostate cancer. Decreased access to care will reverse the significant and continued progress in patient survival.”

Preliminary results from ASTRO’s member survey indicate that these cuts could affect many practices, particularly in rural communities. Initial survey responses reveal that practices may be forced to close their doors, delay or not purchase new equipment, lay off staff, as well as limiting and/or not accepting Medicare patients.  

An urban radiation oncology practice in Nevada reports, “Every year we do more and more with less. Even a 10 percent cut would be devastating for our patients, staff and community. We would need to let employees go, which would be devastating for our economy, and our patients would suffer with decreased access to life-saving cancer care.” 

“These cuts would severely limit our ability to provide quality care to patients close to their homes. We will not be able to sustain staff levels or maintain technology required for high-quality care,” said a rural Texas radiation oncologist.  

For more information:

Related Content

RayCare Oncology Information System Being Shown at ASTRO 2017
News | Radiation Therapy | September 20, 2017
RaySearch will be exhibiting its next-generation oncology information system (OIS) RayCare, among other highlights, at...
ProCure Proton Therapy Center New Jersey Celebrates Five-Year Cancer-Free Milestone for Prostate Cancer Patients
News | Proton Therapy | September 20, 2017
ProCure Proton Therapy Center in Somerset, N.J., recently celebrated the five-year cancer-free milestone for the first...
Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Sponsored Content | Videos | Radiation Therapy | September 08, 2017
The new Visicoil MR is a helically-wound, flexible linear fiducial marker.
User's of Varian's 360 Oncology platform can see all of their current patients and associated tasks at a glance when they log in

User's of Varian's 360 Oncology platform can see all of their current patients and associated tasks at a glance when they log in.

Feature | Oncology Information Management Systems (OIMS) | September 08, 2017 | By Jeff Zagoudis
Cancer is perhaps the most highly personal, complex disease in our world today.
Overlay Init